From Startup Freeline Therapeutics
London, 14 November 2018 – Freeline is pleased to announce the appointment of Brian M. Silver as Chief Financial Officer and Head of Corporate Development. Brian will be based in New York, as the Company establishes offices in the United States.
Brian brings to Freeline 25 years of experience as an investment banker and corporate lawyer. He has for many years focused on the biopharmaceutical and pharmaceutical services sectors, advising clients on a range of transactions including mergers and acquisitions, joint ventures and licensing arrangements, and capital raises across the equity, debt, royalty and convertible securities markets.
Most recently, Brian was a Partner and Head of Biotechnology in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. Prior to that, Brian was a Managing Director in Morgan Stanley’s healthcare investment banking group and a corporate associate at Sullivan & Cromwell. He received a Bachelor of Arts with honours from Harvard College and a Juris Doctor with honours from the University of Chicago Law School.
Anne Prener, Chief Executive Officer of Freeline, said:
“We are delighted to welcome Brian to the Freeline team. He has extensive experience in the investment banking sector that will help us achieve our company’s vision of becoming a leading gene therapy company. Brian’s expertise will be invaluable as we continue to expand our pipeline and our organisation with the aim of bringing life-changing gene therapies to patients.”
Brian Silver, Chief Financial Officer and Head of Corporate Development of Freeline, commented:
“I am excited to join the Freeline team at such a transformational stage in the company’s development. Freeline intends to build a leading global gene therapy company and I look forward to working with my new colleagues as we progress our programmes through the clinic and towards the market”.
+44 (0) 781 8430877
Notes for Editors:
Freeline is a privately-held clinical-stage biotechnology company focused on AAV based gene therapy targeting the liver. Our vision is to create better lives for people suffering from chronic systemic diseases using the potential of gene therapy as a one-time curative treatment. Freeline is headquartered in the UK and has operations in Germany and the US.
Our next generation gene therapy builds upon the pioneering work that Freeline CSO and University College London Professor Amit Nathwani published in the New England Journal of Medicine in 2011 and 2014.
Please visit their site for more information: Freeline Therapeutics.com
All,Biotechnology,Healthcare News,Startup News